人类副流感病毒疫苗的研究进展。
Progress in the development of human parainfluenza virus vaccines.
机构信息
RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Expert Rev Respir Med. 2011 Aug;5(4):515-26. doi: 10.1586/ers.11.32.
Abstract
In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.
摘要
在 5 岁以下儿童中，人副流感病毒（HPIV）是导致住院的急性呼吸道疾病的第二大常见病因，仅次于呼吸道合胞病毒，但优于流感病毒。使用 HPIV 血清型 1、2 和 3（HPIV1、2 和 3）的反向遗传学系统，已经生成了几种减毒 HPIV，并作为鼻内疫苗在成人和儿童中进行了评估。针对 HPIV3 的两种疫苗在 HPIV3 血清阴性婴儿和儿童的 I 期试验中被发现具有良好的耐受性、传染性和免疫原性，应该推进到概念验证试验。针对 HPIV1 和 HPIV2 的疫苗进展较慢，刚刚进入儿科试验。
相似文献
1
Progress in the development of human parainfluenza virus vaccines.人类副流感病毒疫苗的研究进展。
Expert Rev Respir Med. 2011 Aug;5(4):515-26. doi: 10.1586/ers.11.32.
2
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.两种剂量的减毒重组冷适应人副流感病毒 3 型疫苗 rHPIV3cp45 在 HPIV3 血清阴性的幼儿中的安全性和传染性。
Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.
3
Genetic characteristics of human parainfluenza viruses 1-4 associated with acute lower respiratory tract infection in Chinese children, during 2015-2021.2015-2021 年中国儿童急性下呼吸道感染人副流感病毒 1-4 的遗传特征。
Microbiol Spectr. 2024 Oct 3;12(10):e0343223. doi: 10.1128/spectrum.03432-23. Epub 2024 Sep 12.
4
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.利用基于宿主范围减毒的牛副流感病毒3型载体骨架的活cDNA衍生疫苗对恒河猴进行针对呼吸道合胞病毒A和B亚组以及人副流感病毒3型的黏膜免疫。
J Virol. 2002 Feb;76(3):1089-99. doi: 10.1128/jvi.76.3.1089-1099.2002.
5
Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.表达呼吸道合胞病毒（RSV）G蛋白和F蛋白的重组牛/人3型副流感病毒（B/HPIV3）可用于实现针对RSV和HPIV3的同步黏膜免疫。
J Virol. 2001 May;75(10):4594-603. doi: 10.1128/JVI.75.10.4594-4603.2001.
6
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.在P/C和L基因中含有稳定突变的1型人副流感病毒（HPIV1）候选疫苗的减毒作用和效力
Virol J. 2007 Jul 2;4:67. doi: 10.1186/1743-422X-4-67.
7
Seroprevalence of Human Parainfluenza Virus Types 1-4 Among Healthy Children Under 5 Years of Age in Korea.韩国5岁以下健康儿童中1-4型人副流感病毒的血清流行率
Viral Immunol. 2018 Jun;31(5):352-357. doi: 10.1089/vim.2017.0154. Epub 2018 Apr 19.
8
Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.表达人呼吸道合胞病毒（RSV）融合糖蛋白的减毒1型人副流感病毒（HPIV1）作为二价HPIV1/RSV疫苗
J Virol. 2015 Oct;89(20):10319-32. doi: 10.1128/JVI.01380-15. Epub 2015 Jul 29.
9
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.评价两种嵌合牛-人副流感病毒 3 型疫苗在婴幼儿中的效果。
Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.
10
Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.表达人副流感病毒3型血凝素神经氨酸酶（HN）或融合蛋白（F）的仙台病毒重组疫苗可引发保护性免疫，并与第二种重组疫苗联合使用以预防人副流感病毒1型、人副流感病毒3型和呼吸道合胞病毒感染。
Vaccine. 2008 Jun 25;26(27-28):3480-8. doi: 10.1016/j.vaccine.2008.04.022. Epub 2008 May 1.
引用本文的文献
1
Experimental Efficacy of an Alphavirus Vectored RNA Particle Vaccine Against Porcine Parainfluenza Virus-1 in Conventional Weaned Pigs.一种甲病毒载体RNA颗粒疫苗对常规断奶仔猪抗猪副流感病毒-1的实验疗效
Viruses. 2025 Apr 14;17(4):565. doi: 10.3390/v17040565.
2
Development of Primer Panels for Amplicon Sequencing of Human Parainfluenza Viruses Type 1 and 2.用于人1型和2型副流感病毒扩增子测序的引物组的开发
Int J Mol Sci. 2024 Dec 6;25(23):13119. doi: 10.3390/ijms252313119.
3
Drug repurposing to tackle parainfluenza 3 based on multi-similarities and network proximity analysis.基于多相似性和网络邻近性分析的药物重新利用以应对副流感病毒3型
Front Pharmacol. 2024 Oct 1;15:1428925. doi: 10.3389/fphar.2024.1428925. eCollection 2024.
4
Genetic characteristics of human parainfluenza viruses 1-4 associated with acute lower respiratory tract infection in Chinese children, during 2015-2021.2015-2021 年中国儿童急性下呼吸道感染人副流感病毒 1-4 的遗传特征。
Microbiol Spectr. 2024 Oct 3;12(10):e0343223. doi: 10.1128/spectrum.03432-23. Epub 2024 Sep 12.
5
Evaluation of the immunogenicity and protective efficacy of an inactivated vaccine candidate for sheep infected with ovine parainfluenza virus type 3.评估用于感染绵羊副流感病毒 3 型的绵羊的灭活疫苗候选物的免疫原性和保护效力。
Vet Res. 2024 Jun 27;55(1):82. doi: 10.1186/s13567-024-01339-1.
6
Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.通过密码子对去优化而减毒的人副流感病毒 3 疫苗候选株在仓鼠中具有免疫原性和保护作用。
Proc Natl Acad Sci U S A. 2024 Jun 18;121(25):e2316376121. doi: 10.1073/pnas.2316376121. Epub 2024 Jun 11.
7
SARS-CoV-2 and Other Respiratory Viruses in Human Olfactory Pathophysiology.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其他呼吸道病毒在人类嗅觉病理生理学中的作用
Microorganisms. 2024 Mar 7;12(3):540. doi: 10.3390/microorganisms12030540.
8
Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity.从多个个体中鉴定出的具有强大中和活性的 HPIV3 的 IGHV5-51 抗体显示出轻链和 CDRH3 的混杂性。
J Immunol. 2024 May 1;212(9):1450-1456. doi: 10.4049/jimmunol.2300880.
9
Human parainfluenza 2 & 4: Clinical and genetic epidemiology in the UK, 2013-2017, reveals distinct disease features and co-circulating genomic subtypes.人副流感病毒 2 型和 4 型：2013-2017 年英国的临床和遗传流行病学研究显示了不同的疾病特征和共同流行的基因组亚型。
Influenza Other Respir Viruses. 2022 Nov;16(6):1122-1132. doi: 10.1111/irv.13012. Epub 2022 Jun 7.
10
SeV C Protein Plays a Role in Restricting Macrophage Phagocytosis by Limiting the Generation of Intracellular Double-Stranded RNA.仙台病毒C蛋白通过限制细胞内双链RNA的产生在限制巨噬细胞吞噬作用中发挥作用。
Front Microbiol. 2022 Feb 21;13:780534. doi: 10.3389/fmicb.2022.780534. eCollection 2022.
本文引用的文献
1
The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R.人副流感病毒 1 型的 C 蛋白限制双链 RNA 的积累，否则双链 RNA 会激活 MDA5 和蛋白激酶 R。
J Virol. 2011 Feb;85(4):1495-506. doi: 10.1128/JVI.01297-10. Epub 2010 Dec 1.
2
Viral etiology of severe pneumonia among Kenyan infants and children.肯尼亚婴幼儿严重肺炎的病毒病因。
JAMA. 2010 May 26;303(20):2051-7. doi: 10.1001/jama.2010.675.
3
Global, regional, and national causes of child mortality in 2008: a systematic analysis.2008 年全球、区域和国家儿童死亡原因：系统分析。
Lancet. 2010 Jun 5;375(9730):1969-87. doi: 10.1016/S0140-6736(10)60549-1. Epub 2010 May 11.
4
The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen.引发途径影响呼吸道病毒特异性记忆 CD8+T 细胞被残留抗原激活的能力。
J Exp Med. 2010 Jun 7;207(6):1153-60. doi: 10.1084/jem.20090283. Epub 2010 May 10.
5
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.全球儿童因呼吸道合胞病毒导致的急性下呼吸道感染负担：系统评价和荟萃分析。
Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.
6
Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.造血细胞移植（HCT）后呼吸病毒肺炎：支气管肺泡灌洗液样本中病毒载量、血清样本中病毒 RNA 检测与 HCT 临床结局之间的关系。
J Infect Dis. 2010 May 1;201(9):1404-13. doi: 10.1086/651662.
7
Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.实验性减毒活人副流感病毒 2 型疫苗在体外人纤毛气道上皮中的生长受限与在非洲绿猴中的减毒作用相平行。
Vaccine. 2010 Mar 24;28(15):2788-98. doi: 10.1016/j.vaccine.2010.01.050. Epub 2010 Feb 20.
8
Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo.黑色素瘤分化相关基因 5（MDA5）参与体内副粘病毒感染的固有免疫反应。
PLoS Pathog. 2010 Jan 22;6(1):e1000734. doi: 10.1371/journal.ppat.1000734.
9
Croup presentations to emergency departments in Alberta, Canada: a large population-based study.加拿大艾伯塔省急诊科的哮吼表现：一项基于大人群的研究。
Pediatr Pulmonol. 2010 Jan;45(1):83-91. doi: 10.1002/ppul.21162.
10
A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.一种新型的人副流感病毒 1 型（HPIV1）具有分离的 P 和 C 基因，可用于生成 C 基因突变体，以评估其作为活减毒病毒疫苗候选物的作用。
Vaccine. 2010 Jan 8;28(3):767-79. doi: 10.1016/j.vaccine.2009.10.069. Epub 2009 Oct 24.
Zotero 插件